DUX4 and sarcoma: Additionally, extensive collaboration is warranted to more rapidly identify and direct patients with CIC-DUX4 sarcoma to clinical trials that may be effective, such as WEE1 inhibitors (monotherapy or combination) or CDK2-directed therapies, as previously described (4).